(Q34035391)

English

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome (English)

1 reference

Europe PubMed Central

30 July 2017

phase II clinical trial

0 references

thyroid carcinoma

1 reference

based on heuristic

inferred from title

anaplastic thyroid carcinoma

1 reference

based on heuristic

inferred from title

author name string

Colin J Mooney

1

1 reference

Europe PubMed Central

30 July 2017

Govardhanan Nagaiah

2

1 reference

Europe PubMed Central

30 July 2017

Pingfu Fu

3

1 reference

Europe PubMed Central

30 July 2017

Jay K Wasman

4

1 reference

Europe PubMed Central

30 July 2017

Matthew M Cooney

5

1 reference

Europe PubMed Central

30 July 2017

Panos S Savvides

6

1 reference

Europe PubMed Central

30 July 2017

Joseph A Bokar

7

1 reference

Europe PubMed Central

30 July 2017

Afshin Dowlati

8

1 reference

Europe PubMed Central

30 July 2017

Ding Wang

9

1 reference

Europe PubMed Central

30 July 2017

Sanjiv S Agarwala

10

1 reference

Europe PubMed Central

30 July 2017

Susan M Flick

11

1 reference

Europe PubMed Central

30 July 2017

Paul H Hartman

12

1 reference

Europe PubMed Central

30 July 2017

Jose D Ortiz

13

1 reference

Europe PubMed Central

30 July 2017

Pierre N Lavertu

14

1 reference

Europe PubMed Central

30 July 2017

Scot C Remick

15

1 reference

Europe PubMed Central

30 July 2017

publication date

1 March 2009

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

19

1 reference

Europe PubMed Central

30 July 2017

3

1 reference

Europe PubMed Central

30 July 2017

233-240

1 reference

Europe PubMed Central

30 July 2017

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Phase I trial of combretastatin a-4 phosphate with carboplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Combretastatin A4 phosphate: background and current clinical status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Targeting tumour vasculature: the development of combretastatin A4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Clinical multidrug resistance in cancer: a multifactorial problem

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Molecular genetics of human thyroid neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

5 July 2018

Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

29 October 2018

Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

29 October 2018

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

29 October 2018

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

29 October 2018

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913806

29 October 2018

Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anaplastic thyroid carcinoma: a 50-year experience at a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy of thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

https://pubmed.ncbi.nlm.nih.gov/19265494

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1089/THY.2008.0321

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34035391&oldid=1981148645"